Navigation Links
VirtualScopics Schedules Second Quarter 2010 Earnings Announcement
Date:7/26/2010

ROCHESTER, N.Y., July 26 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP), a leading provider of quantitative imaging for clinical trials, announced today that before the market opens on Thursday, August 12, 2010 it will release its second quarter 2010 financial results. The company will host a conference call that morning at 11:00 a.m. EDT.

VirtualScopics' President and Chief Executive Officer, Jeff Markin, and Chief Business and Financial Officer, Molly Henderson, will provide a business update and discuss the company's results for the quarter ended June 30, 2010 during the conference call.

Interested participants should call 877-407-8035 when calling within the United States or +1 201 689 8035 when calling internationally.  This call can also be accessed at www.virtualscopics.com and will be available for 30 days after the call.

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development.  VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images.  In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster.  For more information about VirtualScopics, visit www.virtualscopics.com.

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the backlog and new customer awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to awards of contracts currently under negotiation, the risk that they may not get signed.  Other risks include the company's dependence on its largest customers and risks of contract performance. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

CONTACT:

Tim Ryan

The Shoreham Group LLC

80 Eighth Ave, Ste 1107

New York, NY 10011

+1 212 242 7777 Direct

+1 646 342 6199 Cell

+1 484 377 9916 Fax

tryan@shorehamgroupllc.com 

www.shorehamgroupllc.com 


'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
2. VirtualScopics Project Balance Exceeds a Record $35 Million
3. VirtualScopics to Present at the 8th Annual Bio Investor Forum
4. VirtualScopics Schedules Third Quarter 2009 Earnings Announcement
5. VirtualScopics to Present at the Upcoming OneMedPlace Investment Conference
6. VirtualScopics Receives Issuance in Japan of Prominent Patent
7. VirtualScopics Added to Russell Microcap Index
8. MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
9. Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules
10. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
11. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017 Research and ... for Emerging Medical Device Technologies" report to their offering. ... ... open procedures, general instruments, non-drug coated implantables, large endoscopes, needle ... in use over the last two to three decades for ...
(Date:2/16/2017)...  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ) ... that executive management will participate in the RBC Capital ... 2017. Adrian Adams , Chief Executive Officer, will ... local time on Wednesday, February 22, 2017. ... may be accessed from the Investors section of the ...
(Date:2/16/2017)... Feb. 16, 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... focused on the development and commercialization of innovative ... announced that Vincent J. Angotti has ... of the company,s board of directors, effective Monday, ... decades of experience leading executive and commercial teams ...
Breaking Medicine Technology:
(Date:2/18/2017)... PA (PRWEB) , ... February 17, 2017 , ... Butler ... about the Stannah Stairlift and other Butler products. Ken was impressed with the ... and agreed to endorse the product on his show. This endorsement by Ken ...
(Date:2/18/2017)... ... February 18, 2017 , ... A ... information and contact points to easily connect elderly veterans of America's armed forces ... elder-care funding. It also conveys material on this year's increase in the Veterans ...
(Date:2/17/2017)... ... February 17, 2017 , ... Wells ... the electronic prescribing of controlled and non-controlled substances plus the ability to manage ... in the United States now accept electronic prescriptions, according to the Office of ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective Action & Preventive ... FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... and preventive action (PA)? , The methods share techniques and tools but they ...
(Date:2/17/2017)... ... February 17, 2017 , ... MAP Revenue ... that Karen Pilley has been promoted to Chief Executive Officer. , The ... paradigm – a shift that demands the transition from pay-for-service to pay-for-performance models. ...
Breaking Medicine News(10 mins):